A comprehensive cooperation agreement has reached between Fontacea and Wuxi Biologics

To accelerate the technical development of “anti IL-17A MAb project”and have it commercialized, Shandong Fontacea and Wuxi Biologics have entered an agreement with regarding to process transferring and optimization. The proposal is to promote the research in WBP292 and the development of target medicine, which can help to launch the product and eventually benefit patients.

In Sep 9, 2019, Fontacea signed the exclusive developing grant and commercialization agreement for "anti IL-17A MAb project" with Janssen Pharmaceutica who is owned by Johnson & Johnson.The professional technical CDMO supplier inspection team, leading by CEO Yanliang Chu, inspected and compared R&A abilities, hardware facilities and finished projects among all potential suppliers. After all thorough works, Wuxi Biologics is selected and the agreement as to process transfer is signed.

The quality system in Wuxi Biologics is audited by FDA and EMA,which is able to meet the international quality management standard. They have strengths in R&A and production, and rich experiences in drug development. These can be huge advantages in optimizing processes and developing.